The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
Clinical trial NCT04781192 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04781192
- Sponsor
- University of Kansas Medical Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-22
- Primary completion
- 2025-11-12
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.